On this page

What happened

The published August 17, 2026 version of FDA Import Alert 54-15 covers certain kratom-containing dietary supplements and bulk ingredients. Its Red List includes a Canadian supplier added on that date, 1001387362 Ontario Inc., with an entry for Blue Razz 20 mg 7-OH tablets. Other listed entries date back to 2014. The date therefore identifies an updated published alert and list entry, rather than the first creation of kratom import detention.

Why it matters

The alert directs FDA field staff to detain covered shipments from listed firms without physical examination. It discusses capsules, leaves, powders, extracts and other forms, and sets out FDA’s concerns about safety evidence for the ingredient. This is a border-enforcement mechanism, not a randomized trial or a measurement of cognitive performance. Buyers should distinguish an ingredient description, a supplier-specific listing and the legal treatment of a particular shipment; none is a clinical endorsement.

Scope and limitations

The document states that it is guidance to agency personnel and does not independently bind the public. Its Red List is firm-specific and can change; detention guidance should not be described as a new universal prohibition worldwide. FDA’s published safety concerns also do not establish that every product has identical composition or exposure. The report concerns the U.S. import framework and the August update, with no inference about Turkish legal status or the efficacy of kratom as a nootropic.

This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.

Sources

Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.

← All news